In a neoadjuvant setting, an emerging approach for high-risk melanoma may include immunotherapy and agents like ipilimumab, nivolumab, and pembrolizumab, and targeted therapy for melanomas with BRAF mutations. The gene discussed is BRAF; the disease is melanoma.